Identifying AML patients most likely to benefit from venetoclax using apoptotic gene ratios
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7024
Abstract: Venetoclax is widely used to treat patients with acute myeloid leukemia (AML) who are older or those who are not candidates for intensive chemotherapy. But some patients don't respond well, and it's still hard to… read more here.
Keywords: bcl2l11 pmaip1; gene expression; expression ratios; bcl2 mcl1 ... See more keywords